Skip to content

An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy

An Oncology Nurse Artificial Intelligence Agent to Reduce Cancer Distress of Patients Undergoing Radiotherapy: A Mixed-Methods Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06636188
Acronym
Digi-Coach
Enrollment
138
Registered
2024-10-10
Start date
2026-02-01
Completion date
2028-11-01
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

chatbot, digital health, oncology care

Brief summary

The goal of this clinical trial is to assess the effectiveness of the Digi-Coach chatbot for reducing physical and psychological distress in people undergoing radiotherapy for head and neck cancer. The main question it aims to answer is: How effective is the Digi-Coach chatbot in reducing physical and psychological distress? Researchers will compare Digi-Coach chatbot to usual nursing care to see if Digi-Coach chatbot is effective for reducing physical and psychological distress in people undergoing radiotherapy for head and neck cancer. Participants will have access to the Digi-Coach chatbot during radiotherapy in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer-related concerns in the chatbot.

Detailed description

The goal of this clinical trial is to assess the effectiveness of the Digi-Coach chatbot for reducing physical and psychological distress in people undergoing radiotherapy for head and neck cancer. The main question it aims to answer is: How effective is the Digi-Coach chatbot in reducing physical and psychological distress? Researchers will compare Digi-Coach chatbot to usual nursing care to see if Digi-Coach chatbot is effective for reducing physical and psychological distress in people undergoing radiotherapy for head and neck cancer. A single-blinded parallel randomized controlled trial (RCT allocation ratio = 1:1) will be conducted, with baseline data collection at week 1 (T0) and three follow-up timepoints at week 8 (T1), week 12 (T2) following radiotherapy commencement. Participants in the Treatment-As-Usual group will receive routine onsite nursing care in which the nurse discussed general knowledge of self-care behaviors regarding the management of radiotherapy-related side effects. Participants in the intervention group will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer-related concerns in the chatbot.

Interventions

OTHERDigi-Coach Chatbot

Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.

Sponsors

The University of Hong Kong
Lead SponsorOTHER
Queen Mary Hospital, Hong Kong
CollaboratorOTHER
Queen Elizabeth Hospital, Hong Kong
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 18 and above * are able to read and speak Cantonese or Mandarin fluently * have a new, primary diagnosis of head and neck/laryngeal cancer * are waiting to receive a full course of curative-intent, external beam radiotherapy with or without chemotherapy * have a Karnofsky performance score ≥70 * have distress scored 3 or above on the NCCN distress thermometer

Exclusion criteria

* insufficient command of Chinese * have any other factors precluding the ability to give informed consent or comply with the protocol

Design outcomes

Primary

MeasureTime frameDescription
National Comprehensive Cancer Network Distress Thermometer1 week, 8 weeks, and 12 weeksA 2-item measurement that has participants first rate their distress levels on a scale of 0 (no distress) to 10 (extreme distress) and then self-report their concerns by choosing from a given list of physical, emotional, social, practical, spiritual, or other concerns.

Secondary

MeasureTime frameDescription
Memorial Symptom Assessment Scale1 week, 8 weeks, and 12 weeks32-item comprehensive tool for assessing cancer-related symptom burden with three analysis domains of symptom severity (1 = slight, 4 = very severe), prevalence (1 = rarely, 4 = almost constantly), and distress (0 = not at all, 4 = very much).
Functional Assessment of Cancer Therapy-Head and Neck1 week, 8 weeks, and 12 weeks27 items on the general well-being domain (physical, social/family, emotional, and functional) and 11 items specific to head and neck cancer on a 5-point Likert scale. The total score ranges from 0 to 148; the higher the score, the better the quality of life.

Countries

Hong Kong

Contacts

CONTACTTongyao Wang, PhD
tongyao1@hku.hk852-39102790
PRINCIPAL_INVESTIGATORTongyao Wang, PhD

The University of Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026